Clinical Trial Search

Primary: Percentage of Participants Meeting Overall CRESS Response of at Least 3 of 5 Items at Week 24 — 45.5; 11.1 Percentage of participants

Primary: Maximum Tolerated Dose (Phase 1) — 45 Gy

Primary: Proportion of Patients With Therapeutic Failure — 3; 30 Participants

Primary: Pathologic Response Rate (pRR) for Cohort 1 as Determined by Independent Pathologic Review — 77.3; 80.0; 45.0; 60.0 percentage of participants

Primary: Post-Intervention Motivation Score — 81.01; 72.89 units on a scale

Primary: Maximum Observed Plasma Concentration (Cmax) Following Administration of Bepirovirsen Using Vial and PFS by HCP — 9954.89; 10163.74 Nanograms per milliliters (ng/mL)

Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min

Primary: Feasibility of Ketamine Treatment for Tobacco Use Disorder — 7 Participants

Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…

Primary: Change in Nicotine Self-Administration — -0.8; -0.5 Number of cigarettes

Primary: Median of Uptake of Evuzamitide as Measured by Volume of Interest in Milliliters — 78.7; 253.6; 177.2; 39.6 mL

Primary: Number of Intrusive Memories of Traumatic Event(s) — 14.5; 14.0; 1.0; 10.0 Number of intrusive memories — p=<= 0.001

Primary: Change in Severity of Psoriasis as Measured by Percentage Change in the Psoriasis Area and Severity Index (PASI) Instrument — 17.29; 27.06; 7.07; 20.02 Percent change in…

Primary: Change in Quality of Life in Neurological Disorders Cognitive Function Version 2 (Neuro-QoL CF v2) T-scores at 6 Weeks — 49.9; 49.1; 50; 45.9 T-score — p=0.015

Primary: Number of Participants With SABR Successfully Delivered in One Fraction — 30 Participants